Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02998268 · ClinicalTrials.gov registry record · Phase 2
Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma
A Phase 2 study of Esophageal Adenocarcinoma, sponsored by Weill Medical College of Cornell University.
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 4
- Study locations
NCT02998268 is a Phase 2 study of Esophageal Adenocarcinoma that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 42 participants, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02998268, a Phase 2 study of Esophageal Adenocarcinoma, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a randomized, multicenter phase II study of pembrolizumab in combination with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma to examine the safety and efficacy of the combination of pembrolizumab with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma as assessed by 1 year disease free survival rate.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Taxol
Study Locations (4)
California
- USC Keck School of Medicine, Norris Cancer Center - Los Angeles
Michigan
- University of Michigan - Ann Arbor
New York
- Weill Cornell Medicine - New York
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-03-07 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02998268
The ClinicalTrials.gov registry entry for NCT02998268 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (86% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT02998268 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT02998268 about?
NCT02998268 is a clinical study titled "Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma". This is a randomized, multicenter phase II study of pembrolizumab in combination with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma to examine the safety and efficacy of the combination of pembrolizumab with chemotherapy and chemoradiation in locally advanced esophage...
What is the current status of trial NCT02998268?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2017-03-07. Estimated completion is 2026-03.
What conditions does trial NCT02998268 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma.
What interventions are being tested in trial NCT02998268?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Taxol (DRUG).
Who is sponsoring clinical trial NCT02998268?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02998268 being conducted?
This trial has 4 study locations across California, Michigan, New York, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
RECRUITING · Phase 2
-
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Obeticholic Acid for Prevention in Barrett's Esophagus
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.